Having trouble accessing articles? Reset your cache.

Omeros’ narsoplimab headed for 1H20 submission on back of readout

Omeros is planning a follow-on offering and completion of a rolling BLA for narsoplimab after releasing the first set of pivotal data for the mAb to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, an Orphan indication with

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE